Key facts
- It has raised $95.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($95.0M) in Mar 2021.
- 1 institutional filer reports fund marks on Monte Rosa Therapeutics across 2 filings.
- Monte Rosa Therapeutics has filed 2 Form Ds with the SEC since 2020, most recently Mar 2021 ($95.0M sold to 23 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Monte Rosa Therapeutics
Create free account
No card required
Funding rounds
2 roundsMar 2021Later Stage VC (Series C)$95.0M▮
About Monte Rosa Therapeutics
- Industry
- Biotechnology
PA Mark — not yet priced
Monte Rosa Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Monte Rosa Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest Apr 20251 SEC-registered fund reported 2 fair-value marks on Monte Rosa Therapeutics between Apr 2025 and Apr 2025. Filer-level marks and implied $/share are available to Pro members.